Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anifrolumab in active SLE (TULIP-2)
NCT02446899Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2015
- Primary completion
- Sep 2018
- Modality
- Monoclonal Antibodies
- Countries
- 15
01
Overview
A Phase 3 trial of anifrolumab in systemic lupus erythematosus (SLE), sponsored by AstraZeneca. Started Jul 2015; status: completed.
02
Drugs
anifrolumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02446899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02446899.